GIOTRIF® vs gefitinib for 1^st-line treatment of EGFRm+ NSCLC

14/07/2024 | Author: Boehringer Ingelheim
Document ID: PC-MY-101861

2^nd-generation EGFR-TKIs differ from the 1^st-generation inhibitors (or EGFR-TKIs) in their mechanism of action, with the former having broad spectrum activity and irreversible binding to EGFR receptors, which may result in an improved inhibition of tumour growth. The LUX-Lung 7 trial evaluated the efficacy of 1^st-line GIOTRIF® vs gefitinib in patients with common EGFR mutations.⁴

GIOTRIF® provided faster and improved objective response vs gefitinib⁴

The proportion of patients who achieved an objective response was significantly higher with GIOTRIF® vs gefitinib (70% vs 56%; OR: 1.87 [95% CI: 1.18-2.99]; p=0.0083)
Tumour shrinkage was observed as early as week 4 with a difference between the two arms.⁴

GIOTRIF® demonstrates deeper tumour shrinkage vs gefitinib in L858R patients⁴

The proportion of patients achieving an objective response with GIOTRIF® was more pronounced in patients with L858R mutations⁴
A larger proportion of patients exhibited a ≥50% consistent decrease in tumour size with GIOTRIF® compared to gefitinib (39% vs 21%)⁴

References

1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

2. Wu YL et al. Lancet Oncol. 2014;15(2):213-22.

3. Yang JC et al. Lancet Oncol. 2015;16(2):141-51.

4. Park K et al. Lancet Oncol 2016;17(5):577–89.

Footnotes

CI = confidence interval; EGFR M+=epidermal growth factor receptor mutation positive; EGFR-TKI = epidermal growth factor receptor tyrosine kinase inhibitor; IQR = inter-quartile range; NSCLC=non-small cell lung cancer; PFS=progression-free survival; ORR = objective response rate; OR =odds ratio; OS=overall survival; CI = confidence interval; IQR = inter-quartile range
* LUX-Lung 3 (vs pemetrexed/cisplatin) and LUX-Lung 6 (vs gemcitabine/cisplatin): superior PFS (primary endpoint) and superior OS in Del19 subgroup (secondary endpoint); LUX-Lung 7 (vs gefitinib): superior PFS (primary endpoint).